Biotech in Belgium: news and updates

Gilead galapagos abbvie filgotinib partner rheumatoid

News and Trends 18 Dec 2015

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie‘s shocking abandonment. The Mystery replacement partner has now been revealed as Gilead! Galapagos will receive an upfront payment of €670M from California’s Gilead, consisting of a license fee of €277M and a €393M equity investment in Galapagos. In addition, […]

December 18, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Nov 2015

The 10 Hottest Bioincubators in Europe

A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups. Bioincubators are considered as the first ‘home’ for young biotech companies, providing entrepreneurs access to research laboratories, technology platforms, specific […]

November 10, 2015 - 5 minutesmins - By Nicolas Sainte-Foie

News and Trends 4 Nov 2015

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

And here is the fourth interview I did at BIO-Europe 2015. This time, I am with Andre Hoekema, top-executive from the belgian Biotech success-story, Galapagos. We recently covered extensively the 400-employee company based north of Bruxelles. It made the biggest IPO ever by a EU Biotech on the NASDAQ, raising 270 million euros. It also recently had […]

November 4, 2015 - 1 minutemin - By Philip Hemme

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 27 Oct 2015

Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

The Belgian biomanufacturing company Univercells and the Japanese pharmaceutical company Takeda have signed a strategic partnership agreement. Univercells has closed a €3M equity investment with Takeda Ventures to produce affordable vaccines. Univercells provides single-use cost-efficient bioprocess solutions to lead the next generation in biomanufacturing. Under the terms of the agreement, the two biotechs will launch a […]

October 27, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]

September 29, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Belgium

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Curetis Molecular Diagnostics IPO Exceeds Expectations

The 10 Hottest Bioincubators in Europe

Last exclusive interview from #BIO-Europe 2015: Andre Hoekema, SVP Corporate Development of Galapagos

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!